XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo
This article was originally published in The Pink Sheet Daily
Executive Summary
Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.